See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Liberation Day
Tariffs
Donald Trump
Trade War
Natural Disasters
Social Media
Senate
Trade
Baseball
European Union
US Politics
Stock Markets
Published • loading... • Updated

What is glioblastoma, the aggressive brain cancer that killed former U.S. Rep. Mia Love?

Summary by Afro
Former U.S. Rep. Mia Love, the first Black Republican woman elected to Congress, passed away at 49 after a battle with glioblastoma, an aggressive brain cancer. Despite undergoing surgery and immunotherapy in a clinical trial, the cancer ultimately proved resistant to treatment, highlighting the challenges of this incurable disease. The post What is glioblastoma, the aggressive brain cancer that killed former U.S. Rep. Mia Love? appeared first o…

3 Articles

All
Left
1
Center
Right
AfroAfro
Left

What is glioblastoma, the aggressive brain cancer that killed former U.S. Rep. Mia Love?

Former U.S. Rep. Mia Love, the first Black Republican woman elected to Congress, passed away at 49 after a battle with glioblastoma, an aggressive brain cancer. Despite undergoing surgery and immunotherapy in a clinical trial, the cancer ultimately proved resistant to treatment, highlighting the challenges of this incurable disease. The post What is glioblastoma, the aggressive brain cancer that killed former U.S. Rep. Mia Love? appeared first o…

Read Full Article
Medical XpressMedical Xpress

Study establishes cell death as a driving force in glioblastoma

Glioblastoma, one of the most aggressive and lethal brain cancers, has a five-year survival rate of only 6.9%, according to the National Brain Tumor Society. While the relationship between glioblastoma and cell death, also called necrosis, has been established, it had remained unclear whether it contributed to cancer growth or was merely a byproduct of the disease, said Daniel J Brat, MD, Ph.D., chair and the Magerstadt Professor of Pathology, w…

Read Full Article
portaldoriograndense.comportaldoriograndense.com

Breakthrough in Brain Cancer Treatment: New Therapy Offers Hope for Patients

Calidi Biotherapeutics and City of Hope are advancing CLD-101, a novel therapy for recurrent high-grade glioma, showing promise in Phase 1 clinical trials. The trial is the first to test a multi-dose regimen of neural stem cell-based oncolytic virotherapy, delivering up to four weekly intracerebral doses. Fourteen participants have tolerated the treatment well, signaling new hope in tackling aggressive brain cancer. A $12 million grant from the …

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

portaldoriograndense.com broke the news in on Wednesday, March 26, 2025.
Sources are mostly out of (0)

Similar News Topics

Mia Love

Mia Love

Medical

Medical

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal